跳至主要内容
临床试验/JPRN-UMIN000038587
JPRN-UMIN000038587招募中未知

Efficacy and safety of Sofosbuvir / Velpatasvir combination therapy for type C decompensated cirrhosis - Efficacy and safety of Sofosbuvir / Velpatasvir combination therapy for type C decompensated cirrhosis

ippon Medical School, Division of Gastroenterology and Hepatology, Department of Internal Medicine0 个研究点目标入组 400 人开始时间: 2019年11月15日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
400

研究概览

简要总结

Twelve weeks of sofosbuvir/velpatasvir in real-world clinical practice yielded high SVR rates and acceptable safety profiles in decompensated cirrhotic patients with genotypes 1 and 2. Achievement of SVR not only restored the liver functional reserve but also reduced or spared the administration of drugs for related complications.

研究设计

研究类型
Observational

入排标准

年龄范围
18years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)Patients with a history of hypersensitivity to the ingredients of this drug (2)Patients with severe renal dysfunction (eGFR <30 mL / min / 1.73m2) or renal failure requiring dialysis (3)Patients taking the following drugs Foods containing carbamazepine, phenytoin, phenobarbital, rifampicin, hypericum (St. John's wort) (4)Patient who is pregnant or breastfeeding (5)Patients with hepatocellular carcinoma and other cancers (6)patients who are judged to be inappropriate for participation in the study by the study doctor

研究者

发起方
ippon Medical School, Division of Gastroenterology and Hepatology, Department of Internal Medicine

相似试验